See more : Merriman Holdings, Inc. (MERR) Income Statement Analysis – Financial Results
Complete financial analysis of Bavarian Nordic A/S (BVNRY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bavarian Nordic A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MPHB Capital Berhad (5237.KL) Income Statement Analysis – Financial Results
- Invesque Inc. (IVQ.TO) Income Statement Analysis – Financial Results
- SK bioscience Co.,Ltd. (302440.KS) Income Statement Analysis – Financial Results
- Tiidal Gaming Group Corp. (TIIDF) Income Statement Analysis – Financial Results
- Neometals Ltd (NMT.AX) Income Statement Analysis – Financial Results
Bavarian Nordic A/S (BVNRY)
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.06B | 3.15B | 1.90B | 1.85B | 662.49M | 500.62M | 1.37B | 1.01B | 1.02B | 1.22B | 1.21B | 1.02B | 523.60M | 314.07M | 74.78M | 208.81M | 332.10M | 175.29M | 247.60M | 164.78M | 504.64M | 121.08M | 0.00 |
| Cost of Revenue | 2.46B | 1.45B | 1.33B | 1.20B | 354.76M | 255.12M | 290.62M | 297.79M | 415.14M | 495.08M | 484.71M | 513.55M | 403.39M | 444.47M | 140.10M | 196.66M | 55.12M | 110.80M | 132.23M | 70.25M | 187.19M | 56.45M | 0.00 |
| Gross Profit | 4.60B | 1.70B | 570.32M | 657.29M | 307.73M | 245.50M | 1.08B | 708.95M | 605.42M | 721.73M | 727.80M | 503.08M | 120.21M | -130.40M | -65.32M | 12.15M | 276.99M | 64.50M | 115.37M | 94.53M | 317.45M | 64.62M | 0.00 |
| Gross Profit Ratio | 65.18% | 53.99% | 30.05% | 35.48% | 46.45% | 49.04% | 78.79% | 70.42% | 59.32% | 59.31% | 60.02% | 49.49% | 22.96% | -41.52% | -87.34% | 5.82% | 83.40% | 36.79% | 46.60% | 57.37% | 62.91% | 53.37% | 0.00% |
| Research & Development | 2.35B | 1.18B | 399.16M | 341.42M | 409.28M | 386.30M | 518.41M | 463.17M | 386.81M | 478.93M | 496.61M | 357.44M | 261.72M | 210.83M | 163.98M | 129.65M | 134.96M | 39.28M | 114.38M | 120.44M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 419.85M | 376.02M | 292.92M | 278.15M | 173.42M | 179.96M | 168.06M | 174.21M | 174.79M | 181.02M | 156.99M | 137.76M | 133.40M | 104.58M | 91.48M | 92.04M | -1.57M | -76.37M | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Selling & Marketing | 331.58M | 212.93M | 191.78M | 285.78M | 53.48M | 33.73M | 39.88M | 38.56M | 42.27M | 45.11M | 40.78M | 39.57M | 33.35M | 28.28M | 20.41M | 22.51M | 2.58M | 77.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 751.43M | 588.96M | 484.70M | 563.93M | 226.89M | 213.68M | 207.94M | 212.77M | 217.06M | 226.13M | 197.77M | 177.32M | 166.75M | 132.86M | 111.89M | 92.04M | 1.00M | 819.00K | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -627.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.84M | 206.05M | 228.16M | 45.37M | 120.44M | 60.42M | 59.88M | 71.53M |
| Operating Expenses | 3.11B | 1.77B | 883.86M | 277.70M | 636.18M | 599.98M | 726.34M | 675.94M | 603.87M | 705.06M | 694.38M | 534.76M | 428.48M | 343.69M | 275.87M | 235.53M | 342.01M | 268.26M | 235.14M | 176.85M | 103.41M | 91.27M | 93.48M |
| Cost & Expenses | 5.01B | 3.22B | 2.21B | 1.47B | 990.93M | 855.10M | 1.02B | 973.74M | 1.02B | 1.20B | 1.18B | 1.05B | 831.87M | 788.16M | 415.97M | 432.19M | 397.13M | 379.06M | 367.37M | 247.10M | 290.60M | 147.73M | 93.48M |
| Interest Income | 40.21M | 26.00K | 1.74M | 193.00K | 602.00K | 842.00K | 644.00K | 272.00K | 38.00K | 12.00K | 29.00K | 667.00K | 21.65M | 4.19M | 7.76M | 40.09M | 25.71M | 4.36M | 19.67M | 9.77M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 119.69M | 152.06M | 177.00M | 18.49M | 14.53M | 5.68M | 7.06M | 6.53M | 6.28M | 6.49M | 7.96M | 9.76M | 13.54M | 17.81M | 40.09M | 2.13M | 2.27M | 16.32M | 4.17M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 553.82M | 399.25M | 387.69M | 344.08M | 57.05M | 41.64M | 106.81M | 44.08M | 43.53M | 44.95M | 46.22M | 56.45M | 53.88M | 49.74M | 49.23M | 48.34M | 40.14M | 17.95M | 15.39M | 18.26M | 12.93K | 5.13M | 3.60M |
| EBITDA | 2.14B | 395.40M | 85.94M | 819.13M | -269.21M | -300.47M | 387.63M | 91.98M | 127.69M | 115.58M | 58.92M | 15.69M | -234.24M | -420.16M | -273.23M | -175.05M | -36.06M | -184.58M | -84.71M | -82.32M | 214.05M | -21.52M | -89.88M |
| EBITDA Ratio | 30.33% | 12.55% | 6.59% | 43.72% | -39.15% | -55.51% | 25.19% | 11.20% | 12.45% | 5.40% | 5.28% | 2.69% | -44.45% | -133.78% | -353.15% | -83.83% | -2.48% | -105.30% | -34.21% | -49.96% | 42.42% | -17.77% | 0.00% |
| Operating Income | 1.50B | -3.85M | -263.31M | 449.62M | -316.43M | -354.48M | 353.19M | 33.01M | 1.55M | 16.68M | 33.42M | -31.68M | -308.26M | -474.09M | -341.18M | -223.39M | -65.03M | -203.77M | -119.77M | -82.32M | 214.04M | -26.65M | -93.48M |
| Operating Income Ratio | 21.28% | -0.12% | -13.87% | 24.27% | -47.76% | -70.81% | 25.78% | 3.28% | 0.15% | 1.37% | 2.76% | -3.12% | -58.87% | -150.95% | -456.23% | -106.98% | -19.58% | -116.24% | -48.37% | -49.96% | 42.41% | -22.01% | 0.00% |
| Total Other Income/Expenses | -19.60M | -240.94M | -119.54M | 618.38M | -16.30M | -2.15M | -50.91M | 6.54M | 76.08M | 47.69M | -27.21M | -17.04M | 11.88M | -9.35M | 10.05M | 26.25M | 25.71M | -1.03M | 3.35M | 5.60M | 3.59M | 936.00K | 2.54M |
| Income Before Tax | 1.48B | -331.61M | -454.43M | 281.98M | -344.75M | -356.64M | 302.28M | 39.55M | 77.63M | 64.36M | 6.20M | -48.73M | -296.38M | -483.44M | -331.13M | -183.30M | -50.49M | -204.79M | -116.42M | -76.72M | 217.63M | -25.71M | -90.94M |
| Income Before Tax Ratio | 21.00% | -10.52% | -23.94% | 15.22% | -52.04% | -71.24% | 22.06% | 3.93% | 7.61% | 5.29% | 0.51% | -4.79% | -56.60% | -153.93% | -442.79% | -87.78% | -15.20% | -116.83% | -47.02% | -46.56% | 43.13% | -21.24% | 0.00% |
| Income Tax Expense | 7.75M | 15.77M | 10.35M | 4.46M | 2.03M | 5.29M | 120.94M | 8.95M | 18.20M | 38.42M | 52.93M | 191.28M | 27.96M | 93.53M | 64.86M | 32.94M | 13.01M | -43.86M | -21.69M | -23.71M | 67.06M | -95.83M | 1.14M |
| Net Income | 1.48B | -347.38M | -464.78M | 277.52M | -346.78M | -361.93M | 181.34M | 30.60M | 59.43M | 25.94M | -46.73M | -240.00M | -268.42M | -389.91M | -266.28M | -150.36M | -59.97M | -158.04M | -94.73M | -53.01M | 150.57M | 70.12M | -92.09M |
| Net Income Ratio | 20.89% | -11.03% | -24.49% | 14.98% | -52.34% | -72.30% | 13.24% | 3.04% | 5.82% | 2.13% | -3.85% | -23.61% | -51.26% | -124.15% | -356.07% | -72.01% | -18.06% | -90.16% | -38.26% | -32.17% | 29.84% | 57.91% | 0.00% |
| EPS | 19.20 | -4.93 | -7.37 | 5.13 | -8.50 | -2.96 | 1.50 | 0.26 | 0.55 | 0.26 | -0.47 | -2.43 | -3.41 | -8.83 | -6.96 | -3.31 | -1.38 | -4.13 | -2.88 | -1.88 | 5.01 | 2.64 | -4.52 |
| EPS Diluted | 19.23 | -4.93 | -7.37 | 5.13 | -8.50 | -2.96 | 1.50 | 0.26 | 0.55 | 0.26 | -0.47 | -2.43 | -3.41 | -8.83 | -6.96 | -3.31 | -1.38 | -4.13 | -2.88 | -1.88 | 5.01 | 2.64 | -4.50 |
| Weighted Avg Shares Out | 76.83M | 70.42M | 63.10M | 54.05M | 40.81M | 122.32M | 119.95M | 114.13M | 105.42M | 99.96M | 98.96M | 98.96M | 78.62M | 44.14M | 38.25M | 45.39M | 43.42M | 38.31M | 32.84M | 28.19M | 30.07M | 26.61M | 20.38M |
| Weighted Avg Shares Out (Dil) | 76.71M | 70.42M | 63.10M | 54.05M | 40.81M | 122.32M | 120.91M | 115.03M | 108.47M | 101.79M | 98.96M | 98.96M | 78.62M | 44.14M | 38.25M | 45.39M | 43.42M | 38.31M | 32.84M | 28.19M | 30.07M | 26.61M | 20.45M |
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
COPENHAGEN, Denmark, August 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract of 440,000 doses to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed European country.
Bavarian Nordic will decide this week on mpox vaccine ramp up, CEO says
Danish biotech firm Bavarian Nordic is considering ramping up production of its mpox vaccine without having orders lined up, based on talks this week with the World Health Organisation, the company's CEO told Reuters on Tuesday.
Bavarian Nordic: Jynneos Expansion Amid Global Health Emergencies
Bavarian Nordic specializes in vaccines for infectious diseases and immuno-oncology therapies, with Jynneos being a featured vaccine. Jynneos, Bavarian's vaccine for smallpox and monkeypox, is the only FDA-approved option for both conditions. Bavarian Nordic's 2024 revenue guidance is between $710...
Bavarian Nordic to ramp up production of mpox vaccine
Danish biotech firm Bavarian Nordic said on Saturday it plans to ramp up production of its mpox vaccine and is working closely with all stakeholders to ensure fair access to the vaccine as mpox has been declared a global public...
Mpox Outbreak Sends Stock of Vaccine Maker Bavarian Nordic Soaring
Shares of Bavarian Nordic surged in Danish trading Friday as investors bought into the company with the only approved mpox vaccine in the U.S. and Europe, after the World Health Organization (WHO) declared the fast-breaking outbreak a global health emergency.
Bavarian Nordic shares up 45% this week on mpox outbreak
Biotech firm Bavarian Nordic shares soared over 15% on Friday, another day of substantial gains which analysts have linked to the outbreak of the mpox virus.
Mpox vaccine maker Bavarian Nordic seeks ‘critical' EU approval for teens after WHO declares health emergency
Danish biotech company Bavarian Nordic said Friday that it had submitted data to the Europe Union's drug regulator to extend the use of its mpox vaccine for teenagers. CEO Paul Chaplin told CNBC that the expanded approval for 12 to...
Bavarian Nordic seeks EU approval to extend mpox vaccine to adolescents
Danish biotech Bavarian Nordic said on Friday it had submitted data to the European Union's drug regulator for approval to extend the use of the company's mpox and smallpox vaccine to adolescents aged 12 to 17 years.
Bavarian Nordic stock soars over 15% as WHO declares Mpox a global health emergency
Shares of Bavarian Nordic, a Danish vaccine manufacturer, surged over 15% on Thursday following the World Health Organization's (WHO) declaration of Mpox as a public health emergency. This announcement has drawn significant attention to the Hellerup-based company, which, alongside Emergent...
Health stocks jump as WHO declares mpox global health emergency
Shares of Danish vaccine maker Bavarian Nordic jumped as much as 17% Thursday amid a wider rally for associated healthcare stocks. It comes after the World Health Organization declared an escalating mpox outbreak in Africa as a public health emergency.
Source: https://incomestatements.info
Category: Stock Reports